Photodynamic therapy for prostate cancer - A narrative review
- PMID: 33352313
- DOI: 10.1016/j.pdpdt.2020.102158
Photodynamic therapy for prostate cancer - A narrative review
Abstract
This article is a review of approaches to treatment of low and high-grade prostate cancer including a discussion of active treatment vs. active surveillance for patients with low-grade prostate cancer. In particular, we will review PDT as an option for active treatment of low-grade prostate cancer considered in light of recent clinical trials. The mechanism and clinical methods of PDT application and the key points from clinical trials using PDT for prostate cancer with the photosensitizers m-tetrahydroxyphenyl chloride, protoporphyrin IX, motexafin lutetium, padoporfin, and padeliporfin between the years 2002 and 2017 are reviewed. Recently developed methodologies for photodynamic prostate cancer treatment that are in the experimental stage, photodynamic diagnosis, fluorescence guided resection, and PSMA-targeted PDT will also be discussed.
Keywords: Fluorescence guided resection; PSA; Photodynamic therapy; Prostate cancer; Vascular targeted therapy.
Copyright © 2020 Elsevier B.V. All rights reserved.
Similar articles
-
Photosensitizers in prostate cancer therapy.Oncotarget. 2017 May 2;8(18):30524-30538. doi: 10.18632/oncotarget.15496. Oncotarget. 2017. PMID: 28430624 Free PMC article. Review.
-
Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer.J Environ Pathol Toxicol Oncol. 2006;25(1-2):373-87. doi: 10.1615/jenvironpatholtoxicoloncol.v25.i1-2.230. J Environ Pathol Toxicol Oncol. 2006. PMID: 16566729 Clinical Trial.
-
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.Lancet Oncol. 2017 Feb;18(2):181-191. doi: 10.1016/S1470-2045(16)30661-1. Epub 2016 Dec 20. Lancet Oncol. 2017. PMID: 28007457 Clinical Trial.
-
Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen.Clin Cancer Res. 2008 Aug 1;14(15):4869-76. doi: 10.1158/1078-0432.CCR-08-0317. Clin Cancer Res. 2008. PMID: 18676760 Free PMC article. Clinical Trial.
-
Photodynamic diagnosis and therapy for urothelial carcinoma and prostate cancer: new imaging technology and therapy.Int J Clin Oncol. 2021 Jan;26(1):18-25. doi: 10.1007/s10147-020-01704-y. Epub 2020 May 26. Int J Clin Oncol. 2021. PMID: 32451769 Review.
Cited by
-
Recent Studies in Photodynamic Therapy for Cancer Treatment: From Basic Research to Clinical Trials.Pharmaceutics. 2023 Aug 31;15(9):2257. doi: 10.3390/pharmaceutics15092257. Pharmaceutics. 2023. PMID: 37765226 Free PMC article. Review.
-
The Effect of Photosensitizer Metalation Incorporated into Arene-Ruthenium Assemblies on Prostate Cancer.Int J Mol Sci. 2023 Sep 2;24(17):13614. doi: 10.3390/ijms241713614. Int J Mol Sci. 2023. PMID: 37686420 Free PMC article.
-
Current Strategies in Photodynamic Therapy (PDT) and Photodynamic Diagnostics (PDD) and the Future Potential of Nanotechnology in Cancer Treatment.Pharmaceutics. 2023 Jun 12;15(6):1712. doi: 10.3390/pharmaceutics15061712. Pharmaceutics. 2023. PMID: 37376160 Free PMC article. Review.
-
Multifunctional Photoactive Nanomaterials for Photodynamic Therapy against Tumor: Recent Advancements and Perspectives.Pharmaceutics. 2022 Dec 28;15(1):109. doi: 10.3390/pharmaceutics15010109. Pharmaceutics. 2022. PMID: 36678738 Free PMC article. Review.
-
An Analysis of the Effects of In Vitro Photodynamic Therapy on Prostate Cancer Tissue by Histopathological Examination and Magnetic Resonance Imaging.Int J Mol Sci. 2022 Sep 26;23(19):11354. doi: 10.3390/ijms231911354. Int J Mol Sci. 2022. PMID: 36232657 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
